abbott toxicology limited
abbott toxicology limited Company Information
Company Number
05396234
Website
http://aleretoxicology.co.ukRegistered Address
21 blacklands way, abingdon, oxfordshire, OX14 1DY
Industry
Other professional, scientific and technical activities (not including environmental consultancy or quantity surveying) n.e.c.
Telephone
02070042800
Next Accounts Due
September 2024
Group Structure
View All
Shareholders
alere (uk) holdings ltd 100%
abbott toxicology limited Estimated Valuation
The estimated valuation range for abbott toxicology limited, derived from financial data as of December 2022 and the most recent industry multiples, is between £0 to £23.6m
abbott toxicology limited Estimated Valuation
The estimated valuation range for abbott toxicology limited, derived from financial data as of December 2022 and the most recent industry multiples, is between £0 to £23.6m
abbott toxicology limited Estimated Valuation
The estimated valuation range for abbott toxicology limited, derived from financial data as of December 2022 and the most recent industry multiples, is between £0 to £23.6m
Get a detailed valuation report, edit figures and unlock valuation multiples.
Abbott Toxicology Limited AI Business Plan
In just minutes, we combine Pomanda’s company and industry data with cutting edge Artificial Intelligence to build a comprehensive 27 section business plan. You then have 60 days to tailor the information, decide which sections to include or exclude, and add your own branding logos, images and color scheme to create your perfect plan.
Abbott Toxicology Limited Overview
Abbott Toxicology Limited is a live company located in oxfordshire, OX14 1DY with a Companies House number of 05396234. It operates in the other professional, scientific and technical activities n.e.c. sector, SIC Code 74909. Founded in March 2005, it's largest shareholder is alere (uk) holdings ltd with a 100% stake. Abbott Toxicology Limited is a established, large sized company, Pomanda has estimated its turnover at £31m with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Abbott Toxicology Limited Health Check
Pomanda's financial health check has awarded Abbott Toxicology Limited a 1.5 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 8 areas for improvement. Company Health Check FAQs
3 Strong
1 Regular
8 Weak
Size
annual sales of £31m, make it larger than the average company (£2.6m)
£31m - Abbott Toxicology Limited
£2.6m - Industry AVG
Growth
3 year (CAGR) sales growth of -4%, show it is growing at a slower rate (4.5%)
-4% - Abbott Toxicology Limited
4.5% - Industry AVG
Production
with a gross margin of 33.8%, this company has a higher cost of product (43.7%)
33.8% - Abbott Toxicology Limited
43.7% - Industry AVG
Profitability
an operating margin of -14.5% make it less profitable than the average company (5.8%)
-14.5% - Abbott Toxicology Limited
5.8% - Industry AVG
Employees
with 294 employees, this is above the industry average (21)
294 - Abbott Toxicology Limited
21 - Industry AVG
Pay Structure
on an average salary of £46.5k, the company has an equivalent pay structure (£50.6k)
£46.5k - Abbott Toxicology Limited
£50.6k - Industry AVG
Efficiency
resulting in sales per employee of £105.5k, this is less efficient (£126.1k)
£105.5k - Abbott Toxicology Limited
£126.1k - Industry AVG
Debtor Days
it gets paid by customers after 41 days, this is earlier than average (57 days)
41 days - Abbott Toxicology Limited
57 days - Industry AVG
Creditor Days
its suppliers are paid after 24 days, this is quicker than average (32 days)
24 days - Abbott Toxicology Limited
32 days - Industry AVG
Stock Days
it holds stock equivalent to 104 days, this is more than average (31 days)
104 days - Abbott Toxicology Limited
31 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 15 weeks, this is less cash available to meet short term requirements (26 weeks)
15 weeks - Abbott Toxicology Limited
26 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 136.8%, this is a higher level of debt than the average (54.6%)
136.8% - Abbott Toxicology Limited
54.6% - Industry AVG
abbott toxicology limited Credit Report and Business Information
Abbott Toxicology Limited Competitor Analysis
Perform a competitor analysis for abbott toxicology limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
abbott toxicology limited Ownership
ABBOTT TOXICOLOGY LIMITED group structure
Abbott Toxicology Limited has 5 subsidiary companies.
Ultimate parent company
ALERE SWITZERLAND GMBH
#0132931
2 parents
ABBOTT TOXICOLOGY LIMITED
05396234
5 subsidiaries
abbott toxicology limited directors
Abbott Toxicology Limited currently has 5 directors. The longest serving directors include Mr Kenneth Rowe (Mar 2020) and Mrs Jennifer Deeley (Jan 2022).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Kenneth Rowe | England | 47 years | Mar 2020 | - | Director |
| Mrs Jennifer Deeley | England | 38 years | Jan 2022 | - | Director |
| Mr Michael Clayton | United Kingdom | 50 years | May 2022 | - | Director |
| Mr Michael Clayton | United Kingdom | 50 years | May 2022 | - | Director |
| Ms Nicola Wojciechowicz | England | 46 years | Aug 2022 | - | Director |
ABBOTT TOXICOLOGY LIMITED financials
Abbott Toxicology Limited's latest turnover from December 2022 is £31 million and the company has net assets of -£18.3 million. According to their latest financial statements, Abbott Toxicology Limited has 294 employees and maintains cash reserves of £3.5 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 31,026,000 | 23,166,000 | 22,105,000 | 35,257,000 | 35,999,000 | 36,177,000 | 30,689,000 | 29,750,000 | 30,298,000 | 30,347,000 | 32,529,000 | 0 | 0 | 0 |
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Cost Of Sales | 20,541,000 | 17,348,000 | 17,248,000 | 20,080,000 | 21,455,000 | 20,533,000 | 18,526,000 | 16,830,000 | 17,143,000 | 17,179,000 | 16,940,000 | 0 | ||
| Gross Profit | 10,485,000 | 5,818,000 | 4,857,000 | 15,177,000 | 14,544,000 | 15,644,000 | 12,163,000 | 12,920,000 | 13,155,000 | 13,168,000 | 15,589,000 | 0 | ||
| Admin Expenses | 14,982,000 | 30,849,000 | 16,553,000 | 18,090,000 | 16,741,000 | 13,922,000 | 15,059,000 | 12,741,000 | 12,588,000 | 12,900,000 | 57,220,000 | 117,000 | ||
| Operating Profit | -4,497,000 | -25,031,000 | -11,696,000 | -2,913,000 | -2,197,000 | 1,722,000 | -2,896,000 | 179,000 | 567,000 | 268,000 | -41,631,000 | -117,000 | -1,634,000 | -6,493,000 |
| Interest Payable | 390,000 | 69,000 | 91,000 | 286,000 | 928,000 | 1,698,000 | 1,713,000 | 1,682,000 | 1,113,000 | 2,094,000 | 2,466,000 | 4,126,000 | 3,429,000 | 2,680,000 |
| Interest Receivable | 89,000 | 16,749,000 | 3,000 | 9,000 | 3,000 | 166,000 | 0 | 0 | 0 | 9,000 | 39,000 | 938,000 | 501,000 | 83,000 |
| Pre-Tax Profit | -4,798,000 | -8,351,000 | -11,784,000 | -3,190,000 | -3,122,000 | 190,000 | -4,609,000 | -1,503,000 | -546,000 | -1,817,000 | -44,058,000 | -3,305,000 | -4,562,000 | -9,090,000 |
| Tax | 1,089,000 | 4,179,000 | 205,000 | 142,000 | 76,000 | -424,000 | 273,000 | 10,000 | -84,000 | 1,021,000 | -712,000 | 0 | -499,000 | 432,000 |
| Profit After Tax | -3,709,000 | -4,172,000 | -11,579,000 | -3,048,000 | -3,046,000 | -234,000 | -4,336,000 | -1,493,000 | -630,000 | -796,000 | -44,770,000 | -3,305,000 | -5,061,000 | -8,658,000 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Profit | -3,709,000 | -4,172,000 | -11,579,000 | -3,048,000 | -3,046,000 | -234,000 | -4,336,000 | -1,493,000 | -630,000 | -796,000 | -44,770,000 | -3,305,000 | -5,061,000 | -8,658,000 |
| Employee Costs | 13,658,000 | 13,024,000 | 13,952,000 | 15,729,000 | 15,414,000 | 15,357,000 | 13,529,000 | 13,191,000 | 12,818,000 | 10,154,000 | 11,329,000 | 0 | 1,218,000 | 2,054,000 |
| Number Of Employees | 294 | 317 | 397 | 429 | 458 | 464 | 428 | 403 | 398 | 370 | 383 | 6 | 7 | 6 |
| EBITDA* | -2,826,000 | -23,202,000 | -10,016,000 | -1,043,000 | -492,000 | 3,205,000 | -1,515,000 | 1,409,000 | 1,462,000 | 1,206,000 | -40,813,000 | -117,000 | -1,628,000 | -6,481,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 5,995,000 | 6,476,000 | 7,365,000 | 7,834,000 | 8,954,000 | 8,386,000 | 4,971,000 | 5,107,000 | 4,128,000 | 3,576,000 | 2,922,000 | 0 | 0 | 82,000 |
| Intangible Assets | 719,000 | 1,047,000 | 1,390,000 | 1,336,000 | 1,559,000 | 1,709,000 | 1,846,000 | 2,053,000 | 2,396,000 | 987,000 | 992,000 | 11,000 | 11,000 | 11,000 |
| Investments & Other | 14,296,000 | 15,010,000 | 42,359,000 | 45,649,000 | 60,258,000 | 62,845,000 | 64,517,000 | 67,517,000 | 79,643,000 | 77,680,000 | 88,425,000 | 135,387,000 | 136,634,000 | 136,634,000 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 21,010,000 | 22,533,000 | 51,114,000 | 54,819,000 | 70,771,000 | 72,940,000 | 71,334,000 | 74,677,000 | 86,167,000 | 82,243,000 | 92,339,000 | 135,398,000 | 136,645,000 | 136,727,000 |
| Stock & work in progress | 5,876,000 | 4,218,000 | 3,825,000 | 2,366,000 | 3,285,000 | 3,241,000 | 2,440,000 | 2,418,000 | 3,173,000 | 2,994,000 | 3,768,000 | 0 | 0 | 0 |
| Trade Debtors | 3,522,000 | 3,381,000 | 3,455,000 | 6,798,000 | 8,192,000 | 9,280,000 | 8,030,000 | 8,555,000 | 9,316,000 | 6,341,000 | 6,492,000 | 0 | 14,045,000 | 0 |
| Group Debtors | 9,178,000 | 11,980,000 | 12,926,000 | 13,300,000 | 10,917,000 | 15,572,000 | 21,080,000 | 19,427,000 | 7,380,000 | 4,972,000 | 15,701,000 | 19,235,000 | 0 | 6,196,000 |
| Misc Debtors | 6,593,000 | 5,628,000 | 2,141,000 | 1,458,000 | 1,761,000 | 1,578,000 | 1,521,000 | 1,418,000 | 1,585,000 | 2,099,000 | 1,597,000 | 36,000 | 0 | 904,000 |
| Cash | 3,495,000 | 4,365,000 | 3,580,000 | 3,699,000 | 4,275,000 | 3,616,000 | 4,933,000 | 4,333,000 | 1,406,000 | 1,290,000 | 885,000 | 207,000 | 1,221,000 | 611,000 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 28,664,000 | 29,572,000 | 25,927,000 | 27,621,000 | 28,430,000 | 33,287,000 | 38,004,000 | 36,151,000 | 22,860,000 | 17,696,000 | 28,443,000 | 19,478,000 | 15,266,000 | 7,711,000 |
| total assets | 49,674,000 | 52,105,000 | 77,041,000 | 82,440,000 | 99,201,000 | 106,227,000 | 109,338,000 | 110,828,000 | 109,027,000 | 99,939,000 | 120,782,000 | 154,876,000 | 151,911,000 | 144,438,000 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 1,357,000 | 1,725,000 | 1,345,000 | 2,025,000 | 2,336,000 | 3,271,000 | 2,533,000 | 2,408,000 | 2,201,000 | 1,810,000 | 787,000 | 0 | 0 | 0 |
| Group/Directors Accounts | 7,274,000 | 6,153,000 | 82,182,000 | 73,958,000 | 75,105,000 | 78,788,000 | 83,673,000 | 81,376,000 | 78,952,000 | 68,004,000 | 85,631,000 | 61,664,000 | 55,231,000 | 42,662,000 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 3,077,000 | 2,670,000 | 2,309,000 | 3,551,000 | 3,284,000 | 3,834,000 | 2,717,000 | 2,274,000 | 1,517,000 | 3,147,000 | 3,427,000 | 82,000 | 158,000 | 131,000 |
| total current liabilities | 11,708,000 | 10,548,000 | 85,836,000 | 79,534,000 | 80,725,000 | 85,893,000 | 88,923,000 | 86,058,000 | 82,670,000 | 72,961,000 | 89,845,000 | 61,746,000 | 55,389,000 | 42,793,000 |
| loans | 55,402,000 | 55,000,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3,600,000 | 0 | 0 | 0 |
| provisions | 826,000 | 922,000 | 1,361,000 | 1,915,000 | 826,000 | 133,000 | 714,000 | 733,000 | 832,000 | 715,000 | 287,000 | 0 | 87,000 | 0 |
| total long term liabilities | 56,228,000 | 55,922,000 | 1,361,000 | 1,915,000 | 826,000 | 133,000 | 714,000 | 733,000 | 832,000 | 715,000 | 3,887,000 | 0 | 87,000 | 0 |
| total liabilities | 67,936,000 | 66,470,000 | 87,197,000 | 81,449,000 | 81,551,000 | 86,026,000 | 89,637,000 | 86,791,000 | 83,502,000 | 73,676,000 | 93,732,000 | 61,746,000 | 55,476,000 | 42,793,000 |
| net assets | -18,262,000 | -14,365,000 | -10,156,000 | 991,000 | 17,650,000 | 20,201,000 | 19,701,000 | 24,037,000 | 25,525,000 | 26,263,000 | 27,050,000 | 93,130,000 | 96,435,000 | 101,645,000 |
| total shareholders funds | -18,262,000 | -14,365,000 | -10,156,000 | 991,000 | 17,650,000 | 20,201,000 | 19,701,000 | 24,037,000 | 25,525,000 | 26,263,000 | 27,050,000 | 93,130,000 | 96,435,000 | 101,645,000 |
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | -4,497,000 | -25,031,000 | -11,696,000 | -2,913,000 | -2,197,000 | 1,722,000 | -2,896,000 | 179,000 | 567,000 | 268,000 | -41,631,000 | -117,000 | -1,634,000 | -6,493,000 |
| Depreciation | 1,255,000 | 1,334,000 | 1,341,000 | 1,470,000 | 1,298,000 | 1,109,000 | 1,025,000 | 863,000 | 491,000 | 758,000 | 681,000 | 0 | 6,000 | 12,000 |
| Amortisation | 416,000 | 495,000 | 339,000 | 400,000 | 407,000 | 374,000 | 356,000 | 367,000 | 404,000 | 180,000 | 137,000 | 0 | 0 | 0 |
| Tax | 1,089,000 | 4,179,000 | 205,000 | 142,000 | 76,000 | -424,000 | 273,000 | 10,000 | -84,000 | 1,021,000 | -712,000 | 0 | -499,000 | 432,000 |
| Stock | 1,658,000 | 393,000 | 1,459,000 | -919,000 | 44,000 | 801,000 | 22,000 | -755,000 | 179,000 | -774,000 | 3,768,000 | 0 | 0 | 0 |
| Debtors | -1,696,000 | 2,467,000 | -3,034,000 | 686,000 | -5,560,000 | -4,201,000 | 1,231,000 | 11,119,000 | 4,869,000 | -10,378,000 | 4,519,000 | 5,226,000 | 6,945,000 | 7,100,000 |
| Creditors | -368,000 | 380,000 | -680,000 | -311,000 | -935,000 | 738,000 | 125,000 | 207,000 | 391,000 | 1,023,000 | 787,000 | 0 | 0 | 0 |
| Accruals and Deferred Income | 407,000 | 361,000 | -1,242,000 | 267,000 | -550,000 | 1,117,000 | 443,000 | 757,000 | -1,630,000 | -280,000 | 3,345,000 | -76,000 | 27,000 | 131,000 |
| Deferred Taxes & Provisions | -96,000 | -439,000 | -554,000 | 1,089,000 | 693,000 | -581,000 | -19,000 | -99,000 | 117,000 | 428,000 | 287,000 | -87,000 | 87,000 | 0 |
| Cash flow from operations | -1,756,000 | -21,581,000 | -10,712,000 | 377,000 | 4,308,000 | 7,455,000 | -1,946,000 | -8,080,000 | -4,792,000 | 14,550,000 | -45,393,000 | -5,506,000 | -8,958,000 | -13,018,000 |
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | -714,000 | -27,349,000 | -3,290,000 | -14,609,000 | -2,587,000 | -1,672,000 | -3,000,000 | -12,126,000 | 1,963,000 | -10,745,000 | -46,962,000 | -1,247,000 | 0 | 136,634,000 |
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 1,121,000 | -76,029,000 | 8,224,000 | -1,147,000 | -3,683,000 | -4,885,000 | 2,297,000 | 2,424,000 | 10,948,000 | -17,627,000 | 23,967,000 | 6,433,000 | 12,569,000 | 42,662,000 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 402,000 | 55,000,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3,600,000 | 3,600,000 | 0 | 0 | 0 |
| share issue | ||||||||||||||
| interest | -301,000 | 16,680,000 | -88,000 | -277,000 | -925,000 | -1,532,000 | -1,713,000 | -1,682,000 | -1,113,000 | -2,085,000 | -2,427,000 | -3,188,000 | -2,928,000 | -2,597,000 |
| cash flow from financing | 1,034,000 | -4,386,000 | 8,568,000 | -15,035,000 | -4,113,000 | -5,683,000 | 584,000 | 747,000 | 9,727,000 | -23,303,000 | 3,830,000 | 3,245,000 | 9,492,000 | 150,368,000 |
| cash and cash equivalents | ||||||||||||||
| cash | -870,000 | 785,000 | -119,000 | -576,000 | 659,000 | -1,317,000 | 600,000 | 2,927,000 | 116,000 | 405,000 | 678,000 | -1,014,000 | 610,000 | 611,000 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | -870,000 | 785,000 | -119,000 | -576,000 | 659,000 | -1,317,000 | 600,000 | 2,927,000 | 116,000 | 405,000 | 678,000 | -1,014,000 | 610,000 | 611,000 |
P&L
December 2022turnover
31m
+34%
operating profit
-4.5m
-82%
gross margin
33.8%
+34.56%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2022net assets
-18.3m
+0.27%
total assets
49.7m
-0.05%
cash
3.5m
-0.2%
net assets
Total assets minus all liabilities
abbott toxicology limited company details
company number
05396234
Type
Private limited with Share Capital
industry
74909 - Other professional, scientific and technical activities (not including environmental consultancy or quantity surveying) n.e.c.
incorporation date
March 2005
age
19
accounts
Full Accounts
ultimate parent company
previous names
alere toxicology plc (May 2020)
concateno plc (June 2012)
incorporated
UK
address
21 blacklands way, abingdon, oxfordshire, OX14 1DY
last accounts submitted
December 2022
abbott toxicology limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 5 charges/mortgages relating to abbott toxicology limited. Currently there are 1 open charges and 4 have been satisfied in the past.
abbott toxicology limited Companies House Filings - See Documents
| date | description | view/download |
|---|
